PFIZER

Pfizer Share Price

₹5,125.10 -53.45 (-1.03%)

21 Nov, 2024 14:10

SIP TrendupStart SIP in PFIZER

Start SIP

Performance

  • Low
  • ₹5,100
  • High
  • ₹5,211
  • 52 Week Low
  • ₹3,950
  • 52 Week High
  • ₹6,451
  • Open Price₹5,189
  • Previous Close₹5,179
  • Volume8,080

Investment Returns

  • Over 1 Month -9.66%
  • Over 3 Month -13.16%
  • Over 6 Month + 14.58%
  • Over 1 Year + 28.55%
SIP Lightning

Smart Investing Starts Here Start SIP with Pfizer for Steady Growth!

Invest Now

Pfizer Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.9
  • PEG Ratio
  • 2.1
  • Market Cap Cr
  • 23,446
  • P/B Ratio
  • 6.5
  • Average True Range
  • 156.7
  • EPS
  • 133.78
  • Dividend Yield
  • 0.7
  • MACD Signal
  • -108.69
  • RSI
  • 38.61
  • MFI
  • 36.82

Pfizer Financials

Pfizer Technicals

EMA & SMA

Current Price
₹5,125.10
-53.45 (-1.03%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 14
  • 20 Day
  • ₹5,298.96
  • 50 Day
  • ₹5,437.25
  • 100 Day
  • ₹5,367.83
  • 200 Day
  • ₹5,077.24

Resistance and Support

5204.17 Pivot Speed
  • R3 5,437.28
  • R2 5,368.12
  • R1 5,273.33
  • S1 5,109.38
  • S2 5,040.22
  • S3 4,945.43

What's your outlook on Pfizer?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Pfizer is a global pharmaceutical company offering innovative medicines and vaccines across therapeutic areas, including oncology, cardiology, and infectious diseases. It operates in India, focusing on enhancing patient access to advanced treatments and healthcare solutions.

Pfizer (Nse) has an operating revenue of Rs. 2,238.05 Cr. on a trailing 12-month basis. An annual revenue de-growth of -6% needs improvement, Pre-tax margin of 34% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 52 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Pfizer Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-07-29 Quarterly Results
2024-05-17 Audited Results & Final Dividend
2024-02-09 Quarterly Results
2023-10-28 Quarterly Results
Date Purpose Remarks
2024-08-21 FINAL Rs.35.00 per share(350%)Final Dividend
2023-08-11 FINAL Rs.35.00 per share(350%)Final Dividend
2023-08-11 SPECIAL Rs.5.00 per share(50%)Special Dividend
2022-09-20 SPECIAL Rs.30.00 per share (300%) Special Interim Dividend
2022-08-19 FINAL Rs.35.00 per share(350%)Dividend

Pfizer F&O

Pfizer Shareholding Pattern

63.92%
10.43%
5.52%
3.54%
0.01%
12.15%
4.43%

About Pfizer

  • NSE Symbol
  • PFIZER
  • BSE Symbol
  • 500680
  • Managing Director
  • Ms. Meenakshi Nevatia
  • ISIN
  • INE182A01018

Similar Stocks to Pfizer

Pfizer FAQs

Pfizer share price is ₹5,125 As on 21 November, 2024 | 13:56

The Market Cap of Pfizer is ₹23446.2 Cr As on 21 November, 2024 | 13:56

The P/E ratio of Pfizer is 37.9 As on 21 November, 2024 | 13:56

The PB ratio of Pfizer is 6.5 As on 21 November, 2024 | 13:56

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23